ERBB2 and ductal breast carcinoma in situ: We have previously detailed our clinical results employing a monocyte-derived, LPS-activated, HER-2/neu-expressing dendritic cell immunotherapeutic agent against HER-2/neu-positive ductal carcinoma in situ [13].